DK1730119T3 - Imidazolforbindelser til behandling af neurodegenerative forstyrrelser - Google Patents

Imidazolforbindelser til behandling af neurodegenerative forstyrrelser

Info

Publication number: DK1730119T3
Authority: DK; Denmark
Prior art keywords: treatment; neurodegenerative disorders; imidazole compounds; imidazole; compounds
Prior art date: 2004-03-23

Application number

DK05708746T

Other languages

Danish (da)

English (en)

Inventor

Michael Aaron Brodney

Karen Jean Coffman

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-03-23

Filing date

2005-03-11

Publication date

2008-08-11

2005-03-11 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2008-08-11 Application granted granted Critical

2008-08-11 Publication of DK1730119T3 publication Critical patent/DK1730119T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Psychiatry (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Dermatology (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DK05708746T 2004-03-23 2005-03-11 Imidazolforbindelser til behandling af neurodegenerative forstyrrelser DK1730119T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US55562304P	2004-03-23	2004-03-23
PCT/IB2005/000659 WO2005092864A1 (en)	2004-03-23	2005-03-11	Imidazole compounds for the treatment of neurodegenerative disorders

Publications (1)

Publication Number	Publication Date
DK1730119T3 true DK1730119T3 (da)	2008-08-11

Family

ID=34961257

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK05708746T DK1730119T3 (da)	2004-03-23	2005-03-11	Imidazolforbindelser til behandling af neurodegenerative forstyrrelser

Country Status (43)

Country	Link
US (3)	US7342118B2 (ko)
EP (1)	EP1730119B1 (ko)
JP (2)	JP4054845B2 (ko)
KR (1)	KR100814599B1 (ko)
CN (1)	CN1934091B (ko)
AP (1)	AP2379A (ko)
AR (1)	AR049875A1 (ko)
AT (1)	ATE399155T1 (ko)
AU (1)	AU2005225635B2 (ko)
BR (1)	BRPI0509069B8 (ko)
CA (1)	CA2560580C (ko)
CR (1)	CR8644A (ko)
CY (1)	CY1108347T1 (ko)
DE (1)	DE602005007717D1 (ko)
DK (1)	DK1730119T3 (ko)
DO (1)	DOP2005000040A (ko)
EA (1)	EA011689B1 (ko)
EC (1)	ECSP066879A (ko)
ES (1)	ES2308441T3 (ko)
GE (1)	GEP20084420B (ko)
GT (1)	GT200500060A (ko)
HK (1)	HK1099756A1 (ko)
HN (1)	HN2005000115A (ko)
HR (1)	HRP20080375T3 (ko)
IL (1)	IL177594A0 (ko)
IS (1)	IS8550A (ko)
MA (1)	MA28481B1 (ko)
NL (1)	NL1028598C2 (ko)
NO (1)	NO338263B1 (ko)
NZ (1)	NZ549331A (ko)
PA (1)	PA8627201A1 (ko)
PE (1)	PE20051155A1 (ko)
PL (1)	PL1730119T3 (ko)
PT (1)	PT1730119E (ko)
RS (1)	RS50595B (ko)
SI (1)	SI1730119T1 (ko)
SV (1)	SV2006002055A (ko)
TN (1)	TNSN06300A1 (ko)
TW (1)	TWI372146B (ko)
UA (1)	UA83899C2 (ko)
UY (1)	UY28817A1 (ko)
WO (1)	WO2005092864A1 (ko)
ZA (1)	ZA200606957B (ko)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL1730119T3 (pl) *	2004-03-23	2008-10-31	Pfizer Products Incorporated	Związki imidazolowe do leczenia zaburzeń neurodegeneracyjnych
WO2007034326A2 (en)	2005-09-22	2007-03-29	Pfizer Products Inc.	Imidazole compounds for the treatment of neurological disorders
CA2636077C (en)	2006-01-18	2012-01-03	Amgen Inc.	Thiazole compounds as protein kinase b (pkb) inhibitors
DE102006048042A1 (de) *	2006-10-11	2008-04-17	Bayer Healthcare Ag	Acylaminoimidazole und Acylaminothiazole
WO2009052116A1 (en) *	2007-10-15	2009-04-23	The Salk Institute For Biological Studies	Methods for treating a variety of diseases and conditions, and compounds useful therefor
US20110021625A1 (en) *	2008-01-23	2011-01-27	Lead Chemical Co., Ltd.	Neuronal cell death inhibitor
WO2010096371A2 (en)	2009-02-18	2010-08-26	Boehringer Ingelheim International Gmbh	Heterocyclic compounds which modulate the cb2 receptor
CA2751534A1 (en) *	2009-03-03	2010-09-10	Pfizer Inc.	Novel phenyl imidazoles and phenyl triazoles as gamma-secretase modulators
US8299103B2 (en) *	2009-06-15	2012-10-30	Boehringer Ingelheim International Gmbh	Compounds which selectively modulate the CB2 receptor
US9315454B2 (en)	2010-01-15	2016-04-19	Boehringer Ingelheim International Gmbh	Compounds which modulate the CB2 receptor
US8846936B2 (en)	2010-07-22	2014-09-30	Boehringer Ingelheim International Gmbh	Sulfonyl compounds which modulate the CB2 receptor
RU2465273C2 (ru) *	2010-08-31	2012-10-27	Общество С Ограниченной Ответственностью "Биофарм-Меморейн"	ГЕТЕРОЦИКЛИЧЕСКИЕ НИЗКОМОЛЕКУЛЯРНЫЕ sAPP-МИМЕТИКИ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБЫ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
CA2850707C (en)	2011-10-03	2023-03-21	The University Of Utah Research Foundation	Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
UA110688C2 (uk)	2012-09-21	2016-01-25	Пфайзер Інк.	Біциклічні піридинони
EP2803668A1 (en)	2013-05-17	2014-11-19	Boehringer Ingelheim International Gmbh	Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
WO2015092614A1 (en)	2013-12-20	2015-06-25	Pfizer Inc.	Activating notch alterations in breast cancer
BR112017015693A2 (pt)	2015-02-03	2018-03-20	Pfizer	ciclopropabenzofuranil piridopirazinadionas
RU2741000C2 (ru) *	2015-06-22	2021-01-22	Сумитомо Дайниппон Фарма Ко., Лтд.	Производное 1,4-дизамещенного имидазола
EP3323809A4 (en)	2015-06-22	2019-01-02	Sumitomo Dainippon Pharma Co., Ltd.	Bicyclic heterocyclic amide derivative
US10898469B2 (en)	2016-02-26	2021-01-26	Sumitomo Dainippon Pharma Co., Ltd.	Imidazolylamide derivative
AU2017233898B2 (en)	2016-03-15	2022-12-15	Oryzon Genomics, S.A.	Combinations of LSD1 inhibitors for use in the treatment of solid tumors
WO2018201051A1 (en)	2017-04-28	2018-11-01	Novartis Ag	Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
EP3615055A1 (en)	2017-04-28	2020-03-04	Novartis AG	Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
BR112020024351A2 (pt)	2018-06-01	2021-02-23	Novartis Ag	moléculas de ligação contra bcma e usos das mesmas
US20210196681A1 (en) *	2018-08-27	2021-07-01	Universiteit Maastricht	Selective presenilin-2 gamma-secretase inhibitors
US20220332821A1 (en)	2019-06-24	2022-10-20	Novartis Ag	Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen
IL290428A (en) *	2019-08-09	2022-07-01	Pfizer	Solid forms of (s)-2-(((s)-8,6-difluoro-4,3,2,1-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1- (Neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentamide and their uses
US10590087B1 (en) *	2019-08-09	2020-03-17	Pfizer Inc.	Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof
US11884634B2 (en)	2019-08-09	2024-01-30	Pfizer Inc.	Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide
AU2020360000B2 (en) *	2019-10-02	2023-04-20	Kainos Medicine, Inc.	N-(1H-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient
EP4149975A2 (en)	2020-05-13	2023-03-22	Pfizer Inc.	Methods, therapies and uses for treating cancer
EP4211167A1 (en)	2020-09-14	2023-07-19	Pfizer Inc.	Methods, therapies and uses for treating cancer
EP4255409A1 (en)	2020-12-07	2023-10-11	Cellestia Biotech AG	Pharmaceutical combinations for treating cancer
EP4008324A1 (en)	2020-12-07	2022-06-08	Cellestia Biotech AG	Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer
TW202313020A (zh)	2021-06-02	2023-04-01	瑞士商西萊絲蒂亞生物科技股份有限公司	自體免疫及發炎性疾病的治療方法
US20230089434A1 (en) *	2021-09-01	2023-03-23	Springworks Therapeutics, Inc.	Synthesis of nirogacestat
US11504354B1 (en)	2021-09-08	2022-11-22	SpringWorks Therapeutics Inc..	Chlorinated tetralin compounds and pharmaceutical compositions
WO2023079132A1 (en)	2021-11-08	2023-05-11	Cellestia Biotech Ag	Pharmaceutical combinations for treating cancer
WO2023096954A1 (en) *	2021-11-23	2023-06-01	Teva Pharmaceuticals International Gmbh	Solid state forms of nirogacestat salts
EP4223292A1 (en)	2022-02-07	2023-08-09	Cellestia Biotech AG	Pharmaceutical combinations for treating cancer
WO2023174390A1 (zh) *	2022-03-17	2023-09-21	苏州科睿思制药有限公司	尼罗司他二氢溴酸盐的晶型及其制备方法和用途
US11951096B2 (en)	2022-05-20	2024-04-09	Springworks Therapeutics, Inc.	Treatments with nirogacestat
US11872211B2 (en)	2022-05-20	2024-01-16	Springworks Therapeutics, Inc.	Treatments with nirogacestat

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4512A (en) *		1846-05-09		Smut-machine
US50314A (en) *		1865-10-03		Improvement in telegraph-cables
DE1236426B (de) *	1960-08-25	1967-03-09	Dolomitwerke Gmbh	Verfahren zur Wasseraufbereitung
US5401851A (en)	1992-06-03	1995-03-28	Eli Lilly And Company	Angiotensin II antagonists
JPH07101958A (ja)	1992-10-16	1995-04-18	Takeda Chem Ind Ltd	セフェム化合物、その製造法および抗菌組成物
DE19629816A1 (de)	1996-07-24	1998-01-29	Hoechst Ag	Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
US5760246A (en)	1996-12-17	1998-06-02	Biller; Scott A.	Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
ZA987385B (en)	1997-08-19	2000-04-18	Lilly Co Eli	Growth hormone secretagogues.
US6329342B1 (en)	1997-08-19	2001-12-11	Eli Lilly And Company	Treatment of congestive heart failure with growth hormone secretagogues
ZA987383B (en)	1997-08-19	2000-02-17	Lilly Co Eli	Treatment of congestive heart failure with growth hormone secretagogues.
US6639076B1 (en)	1998-08-18	2003-10-28	Eli Lilly And Company	Growth hormone secretagogues
CO5160260A1 (es) *	1999-02-19	2002-05-30	Lilly Co Eli	Secretagogos de la hormona del crecimiento derivados de imi- dazol 1,4- substituido
US6828331B1 (en)	1999-02-19	2004-12-07	Eli Lilly And Company	Growth hormone secretagogues
US6323315B1 (en)	1999-09-10	2001-11-27	Basf Aktiengesellschaft	Dolastatin peptides
DE10019755A1 (de)	2000-04-20	2001-11-08	Bayer Ag	Neue Aminoaryl/cycloalkylcarbonsäuren als Integrinantagonisten
EP1289526A4 (en)	2000-05-30	2005-03-16	Merck & Co Inc	MELANOCORTIN RECEPTOR AGONISTS
GT200100147A (es) *	2000-07-31	2002-06-25		Derivados de imidazol
JP2002059707A (ja) *	2000-08-23	2002-02-26	Bridgestone Corp	空気入りタイヤ及び空気入りタイヤの製造方法
AU2002223500A1 (en)	2000-11-17	2002-05-27	Novo-Nordisk A/S	Glucagon antagonists/inverse agonists
TW200301698A (en)	2001-12-21	2003-07-16	Bristol Myers Squibb Co	Acridone inhibitors of IMPDH enzyme
US20030171411A1 (en)	2001-12-21	2003-09-11	Kodra Janos Tibor	Amide derivatives as therapeutic agents
AU2003237255B8 (en)	2002-06-05	2010-01-07	Bristol-Myers Squibb Company	Calcitonin gene related peptide receptor antagonists
CA2501803A1 (en)	2002-10-09	2004-04-22	Pfizer Products Inc.	Thiazole compounds for the treatment of neurodegenerative disorders
CA2501799C (en)	2002-10-09	2008-06-17	Pfizer Products Inc.	Pyrazole compounds for treatment of neurodegenerative disorders
JP2006182648A (ja) *	2003-04-08	2006-07-13	Dai Ichi Seiyaku Co Ltd	７員複素環誘導体
JP2006525990A (ja)	2003-05-12	2006-11-16	ファイザー・プロダクツ・インク	神経変性障害の処置のためのイソオキサゾール化合物およびイソチアゾール化合物
CA2533554A1 (en)	2003-08-01	2005-02-10	Pfizer Products Inc.	6-membered heteroaryl compounds for the treatment of neurodegenerative disorders
EP1653952A4 (en)	2003-08-06	2007-04-04	Pfizer Prod Inc	OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEEGENERATIVE DISORDER
WO2005020991A1 (en)	2003-08-21	2005-03-10	Pfizer Products, Inc.	Compounds for the treatment of neurodegenerative disorders
US7348968B2 (en) *	2003-12-02	2008-03-25	Sony Corporation	Wireless force feedback input device
GB0329275D0 (en)	2003-12-18	2004-01-21	Merck Sharp & Dohme	Therapeutic treatment
PL1730119T3 (pl)	2004-03-23	2008-10-31	Pfizer Products Incorporated	Związki imidazolowe do leczenia zaburzeń neurodegeneracyjnych
US7309709B2 (en)	2004-04-01	2007-12-18	Pfizer Inc.	Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders
US7163942B2 (en)	2004-04-01	2007-01-16	Pfizer Inc.	Sulfonamide compounds for the treatment of neurodegenerative disorders
US7232820B2 (en)	2004-04-01	2007-06-19	Pfizer Inc	Thiadiazole-amine compounds for the treatment of neurodegenerative disorders
US7384968B2 (en)	2004-04-01	2008-06-10	Pfizer Inc.	Thiazole-amine compounds for the treatment of neurodegenerative disorders
US20050222227A1 (en)	2004-04-01	2005-10-06	Pfizer Inc	Oxazole-amine compounds for the treatment of neurodegenerative disorders
US7220865B2 (en)	2004-04-01	2007-05-22	Pfizer Inc	Isoxazole-and isothiazole-amine compounds for the treatment of neurodegenerative disorders
WO2007034326A2 (en) *	2005-09-22	2007-03-29	Pfizer Products Inc.	Imidazole compounds for the treatment of neurological disorders

2005
- 2005-03-11 PL PL05708746T patent/PL1730119T3/pl unknown
- 2005-03-11 PT PT05708746T patent/PT1730119E/pt unknown
- 2005-03-11 JP JP2007504496A patent/JP4054845B2/ja active Active
- 2005-03-11 KR KR1020067019625A patent/KR100814599B1/ko active IP Right Grant
- 2005-03-11 EA EA200601494A patent/EA011689B1/ru not_active IP Right Cessation
- 2005-03-11 ES ES05708746T patent/ES2308441T3/es active Active
- 2005-03-11 WO PCT/IB2005/000659 patent/WO2005092864A1/en active Application Filing
- 2005-03-11 EP EP05708746A patent/EP1730119B1/en active Active
- 2005-03-11 DK DK05708746T patent/DK1730119T3/da active
- 2005-03-11 GE GEAP20059630A patent/GEP20084420B/en unknown
- 2005-03-11 CN CN2005800093217A patent/CN1934091B/zh active Active
- 2005-03-11 DE DE602005007717T patent/DE602005007717D1/de active Active
- 2005-03-11 NZ NZ549331A patent/NZ549331A/en not_active IP Right Cessation
- 2005-03-11 UA UAA200610159A patent/UA83899C2/uk unknown
- 2005-03-11 AU AU2005225635A patent/AU2005225635B2/en active Active
- 2005-03-11 RS RSP-2008/0351A patent/RS50595B/sr unknown
- 2005-03-11 US US11/078,898 patent/US7342118B2/en active Active
- 2005-03-11 BR BRPI0509069A patent/BRPI0509069B8/pt active IP Right Grant
- 2005-03-11 SI SI200530339T patent/SI1730119T1/sl unknown
- 2005-03-11 AT AT05708746T patent/ATE399155T1/de active
- 2005-03-11 CA CA002560580A patent/CA2560580C/en active Active
- 2005-03-11 AP AP2006003727A patent/AP2379A/xx active
- 2005-03-18 SV SV2005002055A patent/SV2006002055A/es unknown
- 2005-03-18 TW TW094108466A patent/TWI372146B/zh active
- 2005-03-18 PE PE2005000313A patent/PE20051155A1/es not_active Application Discontinuation
- 2005-03-18 HN HN2005000115A patent/HN2005000115A/es unknown
- 2005-03-21 GT GT200500060A patent/GT200500060A/es unknown
- 2005-03-21 DO DO2005000040A patent/DOP2005000040A/es unknown
- 2005-03-22 NL NL1028598A patent/NL1028598C2/nl active Search and Examination
- 2005-03-22 UY UY28817A patent/UY28817A1/es not_active Application Discontinuation
- 2005-03-22 AR ARP050101116A patent/AR049875A1/es not_active Application Discontinuation
- 2005-03-23 PA PA20058627201A patent/PA8627201A1/es unknown
2006
- 2006-08-21 ZA ZA2006/06957A patent/ZA200606957B/en unknown
- 2006-08-21 IL IL177594A patent/IL177594A0/en active IP Right Grant
- 2006-09-21 CR CR8644A patent/CR8644A/es unknown
- 2006-09-22 MA MA29336A patent/MA28481B1/fr unknown
- 2006-09-22 EC EC2006006879A patent/ECSP066879A/es unknown
- 2006-09-22 TN TNP2006000300A patent/TNSN06300A1/fr unknown
- 2006-10-09 IS IS8550A patent/IS8550A/is unknown
- 2006-10-18 NO NO20064726A patent/NO338263B1/no unknown
2007
- 2007-05-29 HK HK07105652.1A patent/HK1099756A1/xx unknown
- 2007-06-13 JP JP2007156459A patent/JP2007291123A/ja active Pending
2008
- 2008-01-09 US US11/971,272 patent/US7795447B2/en active Active
- 2008-07-29 HR HR20080375T patent/HRP20080375T3/xx unknown
- 2008-09-17 CY CY20081101001T patent/CY1108347T1/el unknown
2010
- 2010-03-12 US US12/723,204 patent/US7951958B2/en active Active

Also Published As

Publication number	Publication date
ATE399155T1 (de)	2008-07-15
JP2007291123A (ja)	2007-11-08
NL1028598A1 (nl)	2005-09-26
HN2005000115A (es)	2009-04-20
EA011689B1 (ru)	2009-04-28
US7951958B2 (en)	2011-05-31
CN1934091A (zh)	2007-03-21
ES2308441T3 (es)	2008-12-01
GT200500060A (es)	2005-10-24
JP2007530525A (ja)	2007-11-01
US7342118B2 (en)	2008-03-11
JP4054845B2 (ja)	2008-03-05
ECSP066879A (es)	2006-11-24
CN1934091B (zh)	2012-02-08
NZ549331A (en)	2010-08-27
NO20064726L (no)	2006-12-22
MA28481B1 (fr)	2007-03-01
PE20051155A1 (es)	2006-01-28
BRPI0509069A (pt)	2007-08-21
AU2005225635A1 (en)	2005-10-06
NL1028598C2 (nl)	2006-01-03
PA8627201A1 (es)	2005-12-23
DE602005007717D1 (de)	2008-08-07
IL177594A0 (en)	2006-12-10
SV2006002055A (es)	2006-05-09
CA2560580C (en)	2008-12-23
US7795447B2 (en)	2010-09-14
AP2006003727A0 (en)	2006-10-31
US20100168107A1 (en)	2010-07-01
PL1730119T3 (pl)	2008-10-31
RS50595B (sr)	2010-05-07
GEP20084420B (en)	2008-07-10
DOP2005000040A (es)	2005-10-21
BRPI0509069B1 (pt)	2019-07-02
SI1730119T1 (sl)	2008-10-31
UA83899C2 (uk)	2008-08-26
US20080227781A1 (en)	2008-09-18
US20050215610A1 (en)	2005-09-29
CR8644A (es)	2006-11-01
CY1108347T1 (el)	2014-02-12
EA200601494A1 (ru)	2007-02-27
CA2560580A1 (en)	2005-10-06
KR20060123651A (ko)	2006-12-01
IS8550A (is)	2006-10-09
TW200539875A (en)	2005-12-16
AR049875A1 (es)	2006-09-13
EP1730119A1 (en)	2006-12-13
BRPI0509069B8 (pt)	2021-05-25
HK1099756A1 (en)	2007-08-24
HRP20080375T3 (en)	2008-09-30
TNSN06300A1 (fr)	2007-12-03
KR100814599B1 (ko)	2008-03-17
EP1730119B1 (en)	2008-06-25
PT1730119E (pt)	2008-09-02
AU2005225635B2 (en)	2010-06-24
AP2379A (en)	2012-03-08
WO2005092864A1 (en)	2005-10-06
UY28817A1 (es)	2005-10-31
TWI372146B (en)	2012-09-11
ZA200606957B (en)	2008-03-26
NO338263B1 (no)	2016-08-08

Publication	Publication Date	Title
DK1730119T3 (da)	2008-08-11	Imidazolforbindelser til behandling af neurodegenerative forstyrrelser
DK2019683T4 (da)	2022-08-29	Indgivelse af vækstfaktorer til behandling af CNS-lidelser
DK1828164T3 (da)	2008-12-08	Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider
DK1778668T3 (da)	2013-09-30	Fremgangsmåde til fremstilling af dihydropteridion
DK2102169T3 (da)	2012-08-27	Indazolylamidderivater til behandling af glucocorticoidreceptormedierede forstyrrelser
DK1685834T3 (da)	2009-07-20	Anvendelse af pinolensyre til behandling af obesitet
DK1869025T6 (da)	2017-01-02	Piperazin-substituerede benzothiophener til behandling af mentale lidelser
DK1701941T3 (da)	2012-08-13	Forbindelser til behandling af sygdomme med celleproliferation
DK1874781T3 (da)	2009-11-02	Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme
DK3403657T3 (da)	2022-02-28	Anvendelse af oligouronater til behandling af slimhyperviskositet
DK1801108T3 (da)	2013-02-18	Morpholinforbindelser til behandling af inflammationer.
DK1928438T3 (da)	2013-04-22	Anvendelse af ibudilast til behandling af stofafhængighed
DK1708992T3 (da)	2007-11-05	Sulfonamidderivater til behandling af sygdomme
DK2117525T3 (da)	2014-02-03	Anvendelse af 1-phenyl-3-dimethylamino-propanforbindelser til behandling af neuropatismerte
DK2209784T3 (da)	2012-10-29	Forbindelser til behandling af hepatitis C
DK1841433T3 (da)	2012-01-16	Præparat til behandling af lidelser i centralnervesystemet
IL177955A0 (en)	2006-12-31	Sulfonamide compounds for the treatment of neurodegenerative disorders
DK2117565T3 (da)	2012-11-19	Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme
DK1907374T3 (da)	2012-10-15	Til behandling af gastrointestinale sygdomme anvendelige benzylpiperazin-derivater
DK1709082T3 (da)	2014-06-16	Sammensætning til behandling af patologi knyttet til MSRV/HERV-W
DK1831223T3 (da)	2013-06-10	Fremgangsmåde til fremstilling af L-biopterin
DK1881830T3 (da)	2009-01-26	4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinolin-derivater til behandling af infertilitet
DK3332789T3 (da)	2022-07-11	Cladribinkur til behandling af multipel sklerose
DK1805316T3 (da)	2009-08-10	Fremgangsmåde til fremstilling af de enantiomere former af cis-3-hydroxycy-
DK1794152T3 (da)	2008-11-17	Fremgangsmåde til fremstilling af enantiomeriske imidazol-forbindelser